Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients

Chiara Camisaschi, Marcella Tazzari, Licia Rivoltini, Chiara Castelli

Research output: Contribution to journalArticle

Abstract

Regulatory T cells (Treg) are a subset of T lymphocytes that in humans represent less than the 10 % of circulating CD4+ T cells. Treg are specialized in the inhibition of the immune responses and play a crucial role in the maintenance of immunological tolerance. Several lines of evidence clearly documented the role of Treg in restraining antitumor immune responses. For this reason, antitumor immunotherapy approaches have been recently associated with drug treatments aimed at depleting Treg or blocking their functions. A summary of the currently used in vivo approaches to limit Treg expansion in cancer patients is here provided. A comprehensive phenotypic and functional monitoring of Treg is crucial for the precise assessment of the effects that these different drug treatments exert on Treg. In this chapter, we will provide guidelines for an accurate ex vivo identification of human Treg. Due to the phenotypic and functional heterogeneity, intrinsic plasticity, and the lack of a unique marker exclusively expressed by human Treg, the clear-cut identification of this T cell subset requires the expert usage of multiparametric flow cytometry analysis (FACS). In this view, a combination of phenotypic and functional assessment of Treg is mandatory. In this chapter, we will describe the most reliable methods to identify and monitor the modulation of human Treg in patients undergoing immunological or drug-based treatments. Protocols to measure ex vivo the suppressive functions of Treg are also provided.

Original languageEnglish
Pages (from-to)201-221
Number of pages21
JournalMethods in molecular biology (Clifton, N.J.)
Volume1139
DOIs
Publication statusPublished - 2014

Fingerprint

Regulatory T-Lymphocytes
T-Lymphocyte Subsets
Pharmaceutical Preparations
Neoplasms
Forensic Anthropology
Immunotherapy
Flow Cytometry
Therapeutics
Maintenance
Guidelines
T-Lymphocytes

Keywords

  • CFSE
  • Immunomagnetic isolation
  • Intracellular staining
  • Multiparametric FACS analysis
  • Regulatory T cells
  • Suppression assay
  • Treg depletion

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Medicine(all)

Cite this

@article{3a486941180b46f6b7630adad51c1d5a,
title = "Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients",
abstract = "Regulatory T cells (Treg) are a subset of T lymphocytes that in humans represent less than the 10 {\%} of circulating CD4+ T cells. Treg are specialized in the inhibition of the immune responses and play a crucial role in the maintenance of immunological tolerance. Several lines of evidence clearly documented the role of Treg in restraining antitumor immune responses. For this reason, antitumor immunotherapy approaches have been recently associated with drug treatments aimed at depleting Treg or blocking their functions. A summary of the currently used in vivo approaches to limit Treg expansion in cancer patients is here provided. A comprehensive phenotypic and functional monitoring of Treg is crucial for the precise assessment of the effects that these different drug treatments exert on Treg. In this chapter, we will provide guidelines for an accurate ex vivo identification of human Treg. Due to the phenotypic and functional heterogeneity, intrinsic plasticity, and the lack of a unique marker exclusively expressed by human Treg, the clear-cut identification of this T cell subset requires the expert usage of multiparametric flow cytometry analysis (FACS). In this view, a combination of phenotypic and functional assessment of Treg is mandatory. In this chapter, we will describe the most reliable methods to identify and monitor the modulation of human Treg in patients undergoing immunological or drug-based treatments. Protocols to measure ex vivo the suppressive functions of Treg are also provided.",
keywords = "CFSE, Immunomagnetic isolation, Intracellular staining, Multiparametric FACS analysis, Regulatory T cells, Suppression assay, Treg depletion",
author = "Chiara Camisaschi and Marcella Tazzari and Licia Rivoltini and Chiara Castelli",
year = "2014",
doi = "10.1007/978-1-4939-0345-0_18",
language = "English",
volume = "1139",
pages = "201--221",
journal = "Methods in Molecular Biology",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients

AU - Camisaschi, Chiara

AU - Tazzari, Marcella

AU - Rivoltini, Licia

AU - Castelli, Chiara

PY - 2014

Y1 - 2014

N2 - Regulatory T cells (Treg) are a subset of T lymphocytes that in humans represent less than the 10 % of circulating CD4+ T cells. Treg are specialized in the inhibition of the immune responses and play a crucial role in the maintenance of immunological tolerance. Several lines of evidence clearly documented the role of Treg in restraining antitumor immune responses. For this reason, antitumor immunotherapy approaches have been recently associated with drug treatments aimed at depleting Treg or blocking their functions. A summary of the currently used in vivo approaches to limit Treg expansion in cancer patients is here provided. A comprehensive phenotypic and functional monitoring of Treg is crucial for the precise assessment of the effects that these different drug treatments exert on Treg. In this chapter, we will provide guidelines for an accurate ex vivo identification of human Treg. Due to the phenotypic and functional heterogeneity, intrinsic plasticity, and the lack of a unique marker exclusively expressed by human Treg, the clear-cut identification of this T cell subset requires the expert usage of multiparametric flow cytometry analysis (FACS). In this view, a combination of phenotypic and functional assessment of Treg is mandatory. In this chapter, we will describe the most reliable methods to identify and monitor the modulation of human Treg in patients undergoing immunological or drug-based treatments. Protocols to measure ex vivo the suppressive functions of Treg are also provided.

AB - Regulatory T cells (Treg) are a subset of T lymphocytes that in humans represent less than the 10 % of circulating CD4+ T cells. Treg are specialized in the inhibition of the immune responses and play a crucial role in the maintenance of immunological tolerance. Several lines of evidence clearly documented the role of Treg in restraining antitumor immune responses. For this reason, antitumor immunotherapy approaches have been recently associated with drug treatments aimed at depleting Treg or blocking their functions. A summary of the currently used in vivo approaches to limit Treg expansion in cancer patients is here provided. A comprehensive phenotypic and functional monitoring of Treg is crucial for the precise assessment of the effects that these different drug treatments exert on Treg. In this chapter, we will provide guidelines for an accurate ex vivo identification of human Treg. Due to the phenotypic and functional heterogeneity, intrinsic plasticity, and the lack of a unique marker exclusively expressed by human Treg, the clear-cut identification of this T cell subset requires the expert usage of multiparametric flow cytometry analysis (FACS). In this view, a combination of phenotypic and functional assessment of Treg is mandatory. In this chapter, we will describe the most reliable methods to identify and monitor the modulation of human Treg in patients undergoing immunological or drug-based treatments. Protocols to measure ex vivo the suppressive functions of Treg are also provided.

KW - CFSE

KW - Immunomagnetic isolation

KW - Intracellular staining

KW - Multiparametric FACS analysis

KW - Regulatory T cells

KW - Suppression assay

KW - Treg depletion

UR - http://www.scopus.com/inward/record.url?scp=84909633833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909633833&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-0345-0_18

DO - 10.1007/978-1-4939-0345-0_18

M3 - Article

C2 - 24619682

AN - SCOPUS:84909633833

VL - 1139

SP - 201

EP - 221

JO - Methods in Molecular Biology

JF - Methods in Molecular Biology

SN - 1064-3745

ER -